Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno‐Safety Technical Committee (ITC)
Mineo Matsumoto(Pharmaceuticals and Medical Devices Agency), Jean G. Sathish(Pfizer (United States)), Rutwij A. Dave(Gilead Sciences (United States)), Smita Salian‐Mehta(Diabetes Australia), Masanori Hiura(Kyowa Kirin (Japan)), Zheng Yang(Renmin Hospital of Wuhan University), Frank R. Brennan(AstraZeneca (United Kingdom)), Payal Arora(Kirin (United States)), Kaushik Datta(Bristol-Myers Squibb (Germany)), Mizuho Suzuki(Pharmaceuticals and Medical Devices Agency), Cris Kampershroer(Sanofi (United States)), Marie Fortin(Jazz Pharmaceuticals (United States)), Suresh Kumar Swaminathan(Janssen (United States)), Joseph Ryan Polli(Novartis (China))
Cited by 15
Related Papers
Loss of Transcription Factor Nuclear Factor-Erythroid 2 (NF-E2) p45-related Factor-2 (Nrf2) Leads to Dysregulation of Immune Functions, Redox Homeostasis, and Intracellular Signaling in Dendritic Cells
|Journal of Biological Chemistry|2012|91
Nuclear Factor-erythroid 2 (NF-E2) p45-related Factor-2 (Nrf2) Modulates Dendritic Cell Immune Function through Regulation of p38 MAPK-cAMP-responsive Element Binding Protein/Activating Transcription Factor 1 Signaling
|Journal of Biological Chemistry|2013|54
<i>In vivo</i> tumor cell rejection induced by NK cell inhibitory receptor blockade: Maintained tolerance to normal cells even in the presence of IL‐2
|European Journal of Immunology|2009|35
Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach
|Regulatory Toxicology and Pharmacology|2022|32